An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Summary

The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).

Timeline

Start

2018-01-24

Primary completion

2019-12-13

Completion

2019-12-13

Outcome

Outcome not reported

Stopped: “This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.”

Drugs

Indications